Cover Image

癌症治疗的复合抗体 (ADC)的开发趋势:分析工具

Conjugated Antibodies in Oncology: Analytical Tool

出版商 BioSeeker Group AB 商品编码 710761
出版日期 内容信息 英文
商品交期: 最快1-2个工作天内
Back to Top
癌症治疗的复合抗体 (ADC)的开发趋势:分析工具 Conjugated Antibodies in Oncology: Analytical Tool
出版日期: 2018年11月01日 内容信息: 英文

本工具,汇整从事癌症治疗的复合抗体 (ADC)开发超过380家公司与其合作夥伴企业的开发平台趋势数据,提供931件开发平台药物 (其中668件处于以300种标的为对象的积极开发阶段) 相关各种数据线上查询。


  • 分析工具
    • 1年的线上查询
    • 内容、特集的隔周更新
    • 开发平台警报
    • 线上支持
  • 「1stOncology NewsDesk」的存取
    • 新闻快报的实况串流 (每5分钟更新一次)
    • 各种流通管道
      • 社群媒体
      • 临床试验
      • 智能财产权
      • 财务数据
      • 新闻稿


  • 目标侦察
  • 初期、后期阶段的开发平台分析
  • 生物标记/搭配诊断药分析
  • 契约、联盟分析
  • 联合治疗分析
  • 临床试验结果分析
  • 适应症的选择、扩大分析
  • First-in-Class分析
  • 托曳重新定位
  • 开发平台分析:各标的途径


Product Code: BSG21826

The first Antibody-Drug Conjugate (ADC) to receive marketing approval from the US Food and Drug Administration (FDA) was gemtuzumab ozogamicin (Mylotarg) in 2000 which represents a powerful, emerging novel class of anticancer treatment agents that combines the selectivity of targeted treatment with the cytotoxic potency of chemotherapy drugs.

Conjugated Antibodies in Oncology: Analytical Tool is the most up to date and comprehensive commercial pipeline review and competitive assessment available on this hot and fast moving area in oncology. This unique product is truly the only one of its kind and is designed to give you a competitive edge in your ADC drug intelligence.

Your Conjugated Antibodies in Oncology: Analytical Tool is based on two decades of proven methodology in serving clients with interest in:

  • Target Scouting
  • Early & Late Stage Pipeline Analysis
  • Biomarker/Companion Diagnostic Analysis (featured below)
  • Deal & Alliance Analysis
  • Conference surveillance of world leading cancer meetings (featured below)
  • Combination Therapy Analysis (featured below)
  • Clinical Trial Results Analysis
  • Indication Selection & Expansion Analysis
  • First-in-Class Analysis
  • Drug Repositioning
  • Pipeline Analysis by Targeted Pathways
  • Instantly generate drug profiles, drug target profiles and company profiles (including Business Development & Licensing contacts)

Analytical Tools transform your computer's desktop into a high capacity workbench within your area of choice. Even before launching this tool you have already eliminated hundreds of hours of work needed to discover, process and piece together the thousands of sources that our team of oncology dedicated and highly experienced contents specialists have done on your behalf.

Your Conjugated Antibodies in Oncology: Analytical Tool covers more than 380 companies plus partners who are today developing 931 ADC drugs where of 668 are in active development in cancer across 300 different targets. Any data and/or analysis from the Analytical Tool is yours to keep and data/graphs/tables can be easily exported into Excel/PDF and various graphic formats for mixing with your own proprietary information.

Let our expertise work for you

With a simple point and click interface you can navigate the environment of current development, drill down into specific areas such as ongoing combination trials, biomarker analysis, selected scientific abstracts etc. and generate drug profiles, drug target profiles and company profiles (including Business Development & Licensing contacts). Any analysis generated by you is packed with presentation-ready graphs and tables to use in your reports and presentations.

Your key to access development at the world-leading cancer meetings

The Conjugated Antibodies in Oncology: Analytical Tool is continuously updated according to twelve of the world's most influential meetings in oncology (AACR, ASCO, ASGCT, ASH, CIMT, EHA, EORTC-NCI-AACR, ESMO, SITC and BIO (International, Europe and Asia). If you are not able to attend any of the conference(s) in person, this Analytical Tool ensures that you are not missing out on the important take home messages you need to know about.

Run combination therapy analysis like no other

The Conjugated Antibodies in Oncology: Analytical Tool delivers comprehensive combination therapy analysis, allowing you to analyze combination therapies from multiple perspectives; from a single drug to virtually any cross section of oncology drugs of interest.

Unparalleled biomarker surveillance

We also provide an outstanding oncology clinical biomarker surveillance & analysis, highlighting clinical phenotyping and patient stratification in trials. This analysis is based on our monitoring of the presence and usage of more than 1,000 biomarkers across tens of thousands of cancer clinical trials.

Support and inspiration at your finger-tips

You also have access to a great selection of How-to Training Videos showing best practice approaches to aspects such as competitive pipeline analysis right through to many real world case examples put forward by other users of our Analytical Tools.

A tool to grow with and keep you informed

Unlike a static report which just represents a particular snapshot in time, all of the Analytical Tools come with one year of online access to twice-weekly updates in both contents and features, pipeline alerts and online support etc. You can choose to renew your access to these updates and support on a yearly basis or go over to our industry leading full service platform covering all oncology drug development, 1stOncology.

System Requirements

  • Browser Application (Supports: Internet Explorer, FireFox, Chrome and Safari))
  • Internet access
Back to Top